pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN
Regeneron UK
Regeneron UK Limited
Regeneron UK clinical programs — 60 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Tarrytown, USA
- Employees
- 16,715
- Programs
- 493
- Drugs
- 98
- Patents
- 837
Regeneron UK projects
60 ClinicalTrials.gov programs sponsored by Regeneron UK.
Regeneron UK has 60 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Intravitreal aflibercept injection 2.0mg
Regeneron UK Limited
Polypoidal Choroidal Vasculopathy
1 trial -
Pozelimab
Regeneron UK Limited
CHAPLE Disease
1 trial -
Praluent
Regeneron UK Limited
Heterozygous Familial Hypercholesterolemia
1 trial -
Praluent (Alirocumab)
Regeneron UK Limited
Hypercholesterolemia
1 trial -
Rescue Intravitreal Aflibercept Injection
Regeneron UK Limited
Neovascular Polypoidal Choroidal Vasculopathy
1 trial -
SAR231893
Regeneron UK Limited
Asthma
1 trial -
Sarilumab
Regeneron UK Limited
Polymyalgia Rheumatica
1 trial -
Sarilumab
Regeneron UK Limited
Rheumatoid Arthritis
8 trials -
aflibercept 2.0 mg
Regeneron UK Limited
Diabetic Macular Edema
1 trial -
aflibercept 2.0 mg
Regeneron UK Limited
Age Related Macular Degeneration
1 trial -
dupilumab
Regeneron UK Limited
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
dupilumab
Regeneron UK Limited
Severe Atopic Dermatitis (AD)
1 trial
Frequently asked questions
How many clinical projects does Regeneron UK have?
60 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.